McKinsey September 25, 2024
Alex Devereson with Navraj Nagra

As head of R&D at Novo Nordisk, Marcus Schindler is leading the company’s efforts to embrace external innovation and expand into new therapeutic areas with AI as a powerful catalyst for progress.

In this episode of Eureka!, a McKinsey podcast on innovation in life sciences R&D, hosts Navraj Nagra and Alex Devereson speak to Marcus Schindler, executive vice president for R&D and chief scientific officer at Novo Nordisk. They discuss how Novo Nordisk is expanding its external innovation capabilities and moving into new therapeutic areas. They also explore his efforts to embed AI throughout the R&D organization, establish Novo Nordisk as a leader of AI ecosystems (in Boston and beyond), and eventually advance from treating diseases to curing them, with...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Conferences / Podcast, Pharma / Biotech, Trends
Related Articles:
Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry

Share This Article